Pharmaceutical

Esperion snags US label expansion for cardiovascular disease drugs

Esperion Therapeutics’ Nexletol and Nexlizet are now available for patients with cardiovascular risk in the US.

Mar 26, 2024 - 00:00
Esperion snags US label expansion for cardiovascular disease drugs
Esperion Therapeutics’ Nexletol and Nexlizet are now available for patients with cardiovascular risk in the US.
Read the original article

Tags:

Previous Article

CRISPR-based assay could revolutionise diagnosis of NTM infections

Next Article

AriBio licenses Alzheimer’s pill in China for up to $770m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: I declined to share my medical data with advertisers at my doctor’s office. One company claimed otherwise

Opinion: I declined to share my medical data with adver...

Apr 7, 2023

STAT+: To make immunotherapy safe for brain tumors, researchers will have to tackle new risks

STAT+: To make immunotherapy safe for brain tumors, res...

Apr 7, 2023

Why it won’t be so easy for medicine to displace BMI

Why it won’t be so easy for medicine to displace BMI

Jun 16, 2023